Sugammadex ED90 Dose in the Obese Patients

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg but no studies were found with obese patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faculdade de Ciências Médicas da Santa Casa de São Paulo

Criteria

Inclusion Criteria:

• a body mass index ≥ 40 kg/m2

• bariatric surgery

• informed consent signed

Exclusion Criteria:

• history of neuromuscular diseases,

• use of drugs that could interfere with neuromuscular transmission,

• allergy to neuromuscular agents of the aminosteroids class,

• anticipated difficulty in airway management,

• renal failure